The Effect of Imlunestrant on CYP2C8, CYP2C19, CYP2D6, P-gp, and BCRP Activity and the Effect of P-gp Inhibition on Imlunestrant Pharmacokinetics in Healthy Women of Non-childbearing Potential
Latest Information Update: 28 Nov 2022
At a glance
- Drugs Dextromethorphan (Primary) ; Digoxin (Primary) ; Imlunestrant (Primary) ; Omeprazole (Primary) ; Quinidine (Primary) ; Repaglinide (Primary) ; Rosuvastatin (Primary)
- Indications Breast cancer; Endometrial cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Nov 2022 Status changed from active, no longer recruiting to completed.
- 18 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2022 Status changed from not yet recruiting to recruiting.